pirenzepine has been researched along with Weight Gain in 85 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
Weight Gain: Increase in BODY WEIGHT over existing weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The primary goal of the study was to determine if olanzapine is effective in producing weight gain in patients with anorexia nervosa." | 9.10 | Olanzapine in the treatment of anorexia nervosa: an open label trial. ( Bannon, YS; Powers, PS; Santana, CA, 2002) |
| "Since increased norepinephrine availability may account for the weight-reducing effect of appetite suppressants, the authors hypothesized that the addition of the selective norepinephrine reuptake inhibitor reboxetine may prevent or attenuate olanzapine-induced weight gain." | 9.10 | Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. ( Faragian, S; Fuchs, C; Isaacs, I; Poyurovsky, M; Schneidman, M; Weizman, A; Weizman, R, 2003) |
| "Significant weight gain is a side effect associated with olanzapine treatment in some patients." | 9.10 | Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients. ( Bogenschutz, M; Bustillo, JR; Hammond, R; Keith, S; Lauriello, J; Parker, K; Rowland, L, 2003) |
| "Weight gain is associated with treatment with olanzapine and other psychotropic agents." | 9.10 | Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial. ( Allison, DB; Breier, A; Cavazzoni, P; Roychowdhury, SM; Tanaka, Y, 2003) |
| "The aim of the present study was to investigate the effect of adjunctive olanzapine in patients with obsessive-compulsive disorder (OCD) refractory to paroxetine." | 9.10 | Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder. ( Cedro, C; D'Amico, G; D'Arrigo, C; Di Rosa, AE; La Torre, D; Muscatello, MR; Pandolfo, G; Spina, E; Zoccali, R, 2003) |
| "These results suggest that fluoxetine coadministration is clinically ineffective and cannot attenuate olanzapine-induced weight gain." | 9.10 | Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. ( Fuchs, C; Gil-Ad, I; Maayan, R; Pashinian, A; Poyurovsky, M; Schneidman, M; Weizman, A, 2002) |
| "A pilot study was conducted to evaluate the effect of nizatidine on olanzapine-associated weight gain (OAWG) in ten patients with schizophrenia and schizophreniform disorder in Korea." | 9.10 | Effect of nizatidine on olanzapine-associated weight gain in schizophrenic patients in Korea: a pilot study. ( Bahk, WM; Kim, JJ; Lee, C; Lee, CU; Lee, KU; Lee, SJ; Pae, CU; Paik, IH, 2003) |
| "Olanzapine-induced weight gain is associated with a general increase in caloric intake." | 9.10 | Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. ( Apter, A; Constantini, N; Falk, B; Frishman, S; Gothelf, D; Kairi, M; Phillip, M; Poraz, I; Singer, P; Weizman, A; Zalsman, G; Zigel, L, 2002) |
| "It has been reported that nizatidine may reduce the weight gain in schizophrenic patients receiving olanzapine treatment." | 9.10 | Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain. ( Atmaca, M; Kuloglu, M; Tezcan, E; Ustundag, B, 2003) |
| "The aim of this study was to estimate the long-term effectiveness of olanzapine as adjunctive therapy in patients with bipolar disorder who exhibited an inadequate response to mood stabilizers." | 9.09 | Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder. ( Benabarre, A; Colom, F; Corbella, B; Gastó, C; Gilaberte, I; Martínez-Arán, A; Reinares, M; Tohen, M; Vieta, E, 2001) |
| "The authors used a prospective, controlled, open study comparing body weight, body mass index, and related biological measures in mentally and physically healthy volunteers and olanzapine-treated patients with schizophrenia." | 9.09 | Association of olanzapine-induced weight gain with an increase in body fat. ( Ebenbichler, C; Eder, U; Fleischhacker, WW; Hofer, A; Hummer, M; Kemmler, G; Lechleitner, M; Mangweth, B; Weiss, E, 2001) |
| "This first clinical study of olanzapine in Japanese patients with schizophrenia was conducted to investigate the efficacy and safety of olanzapine." | 9.09 | Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: results of an open-label multicenter study in Japan. ( Ishigooka, J; Miura, S; Murasaki, M, 2001) |
| "Open-label olanzapine treatment was efficacious and well tolerated in the treatment of acute mania in youths with bipolar disorder." | 9.09 | A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. ( Biederman, J; Feldman, PD; Frazier, JA; Garfield, SB; Gonzalez-Heydrich, J; Jacobs, TG; Kim, GS; Nowlin, ZM; Rater, MA; Risser, RC; Sohma, M; Tarazi, RA; Tohen, M; Toma, V, 2001) |
| "Adding the atypical neuroleptic risperidone to a serotonin reuptake inhibitor (SRI) has benefited patients with treatment-refractory obsessive-compulsive disorder (OCD)." | 9.09 | Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. ( Elliott, MA; Koran, LM; Ringold, AL, 2000) |
| " haloperidol) therapy, better clinical outcome, lower BBMI, and nonwhite race significantly affected weight gain." | 9.09 | Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. ( Basson, BR; Gilmore, JA; Kinon, BJ; Szymanski, KA; Taylor, CC; Tollefson, GD, 2001) |
| "Subjects (N=377) who met DSM-IV criteria for schizophrenia or schizoaffective disorder were randomly assigned to receive 2-6 mg/day of risperidone (mean modal dose=4." | 9.09 | A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. ( Conley, RR; Mahmoud, R, 2001) |
| " Amantadine (100-300 mg/day) was started in 12 patients having a mean weight gain of 7." | 9.09 | Effect of amantadine on weight gain during olanzapine treatment. ( Deberdt, W; Floris, M; Lejeune, J, 2001) |
| "Weight change and the weight-related health factors of nonfasting serum glucose, serum cholesterol, and diastolic blood pressure levels were analyzed in patients with DSM-III-R schizophrenia and related disorders who received treatment with olanzapine for up to 3 years, and comparisons were made to patients treated with haloperidol." | 9.09 | Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. ( Basson, BR; Gilmore, JA; Kinon, BJ; Tollefson, GD, 2001) |
| "The authors explored the binge eating symptomatology in 74 patients receiving clozapine (N = 57) or olanzapine (N = 17), and compared body mass index (BMI, kg/m(2)) and weight gain in patients with and without binge eating symptomatology." | 7.72 | Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine. ( Hebebrand, J; König, IR; Linden, A; Martin, M; Remschmidt, H; Theisen, FM, 2003) |
| "Clinically relevant weight gain is clearly associated with olanzapine, and to lesser extent, with haloperidol and risperidone." | 7.72 | Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. ( Bobes, J; Fernández, I; Garcia-Garcia, M; García-Portilla, MP; Hernández, G; Rejas, J; Rico-Villademoros, F, 2003) |
| "The increasing use of olanzapine for treating adolescent patients has brought with it greater awareness of the recognized side effects of this medication, especially weight gain." | 7.72 | Hyperglycemia from olanzapine treatment in adolescents. ( Bloch, Y; Gothelf, D; Levkovitz, Y; Mendlovic, S; Ratzoni, G; Vardi, O, 2003) |
| "The role of olanzapine in treatment-resistant schizophrenia is still unresolved." | 7.71 | Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial. ( Chakos, M; Citrome, L; Czobor, P; Iskander, A; Lieberman, J; Lindenmayer, JP; Parker, B; Sheitman, B; Volavka, J, 2001) |
| "Conventional as well as newer antipsychotics cause weight gain, and, in the regulation of body weight, both insulin and leptin are hormones involved." | 7.71 | Insulin and leptin levels in patients with schizophrenia or related psychoses--a comparison between different antipsychotic agents. ( Hulting, AL; Melkersson, KI, 2001) |
| "This study evaluated the effectiveness of a Weight Watchers program for patients with schizophrenia who had olanzapine-related weight gain and ascertained whether the severity of patients' psychiatric symptoms was correlated with the patients' success in losing weight." | 7.71 | A program for treating olanzapine-related weight gain. ( Ball, MP; Buchanan, RW; Coons, VB, 2001) |
| " In order to determine whether newer antipsychotic agents differ from each other with respect to weight gain, we compared two cohorts of patients with DSM-IV schizophrenia who had newly started treatment with either risperidone or olanzapine." | 7.71 | Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone. ( Ayrton, Z; Brar, JS; Ganguli, R, 2001) |
| "We describe here a case of olanzapine associated weight gain, hyperglycemia and neuroleptic malignant syndrome in a 64 year-old woman with a significant medical history." | 7.71 | Olanzapine associated weight gain, hyperglycemia and neuroleptic malignant syndrome: case report. ( Gibson, B; Kang, N; Malyuk, R; Procyshyn, RM, 2002) |
| "To evaluate weight gain associated with olanzapine, risperidone, and haloperidol treatment and its clinical risk factors in adolescent patients." | 7.71 | Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. ( Apter, A; Brand-Gothelf, A; Gal, G; Gothelf, D; Kikinzon, L; Phillip, M; Ratzoni, G; Reidman, J; Weizman, R, 2002) |
| "H(2) antagonist treatment with olanzapine may be a valid medical strategy in preventing and/or reducing weight gain in patients with schizophrenia." | 7.70 | H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients. ( Bravi, D; Guarneri, L; Sacchetti, E, 2000) |
| "Weight gain induced by clozapine or olanzapine appears to be associated with an increase in leptin level that cannot be attributed to dietary changes upon hospitalization." | 7.70 | Body weight and leptin plasma levels during treatment with antipsychotic drugs. ( Haack, M; Hinze-Selch, D; Kraus, T; Kühn, M; Pollmächer, T; Schuld, A; Uhr, M, 1999) |
| "AP-induced weight gain is also associated with disruption of the hypothalamic-pituitary-gonadal axis." | 6.71 | The relationship of changes in leptin, neuropeptide Y and reproductive hormones to antipsychotic induced weight gain. ( de Castella, AR; Fitzgerald, PB; Kulkarni, J; Morris, MJ; Scaffidi, A, 2003) |
| "The primary goal of the study was to determine if olanzapine is effective in producing weight gain in patients with anorexia nervosa." | 5.10 | Olanzapine in the treatment of anorexia nervosa: an open label trial. ( Bannon, YS; Powers, PS; Santana, CA, 2002) |
| "These results suggest that fluoxetine coadministration is clinically ineffective and cannot attenuate olanzapine-induced weight gain." | 5.10 | Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. ( Fuchs, C; Gil-Ad, I; Maayan, R; Pashinian, A; Poyurovsky, M; Schneidman, M; Weizman, A, 2002) |
| "The aim of the present study was to investigate the effect of adjunctive olanzapine in patients with obsessive-compulsive disorder (OCD) refractory to paroxetine." | 5.10 | Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder. ( Cedro, C; D'Amico, G; D'Arrigo, C; Di Rosa, AE; La Torre, D; Muscatello, MR; Pandolfo, G; Spina, E; Zoccali, R, 2003) |
| "A pilot study was conducted to evaluate the effect of nizatidine on olanzapine-associated weight gain (OAWG) in ten patients with schizophrenia and schizophreniform disorder in Korea." | 5.10 | Effect of nizatidine on olanzapine-associated weight gain in schizophrenic patients in Korea: a pilot study. ( Bahk, WM; Kim, JJ; Lee, C; Lee, CU; Lee, KU; Lee, SJ; Pae, CU; Paik, IH, 2003) |
| " The authors' goal was to assess the effects of clozapine, olanzapine, risperidone, and haloperidol on glucose and cholesterol levels in hospitalized patients with schizophrenia or schizoaffective disorder during a randomized double-blind 14-week trial." | 5.10 | Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2003) |
| "Since increased norepinephrine availability may account for the weight-reducing effect of appetite suppressants, the authors hypothesized that the addition of the selective norepinephrine reuptake inhibitor reboxetine may prevent or attenuate olanzapine-induced weight gain." | 5.10 | Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. ( Faragian, S; Fuchs, C; Isaacs, I; Poyurovsky, M; Schneidman, M; Weizman, A; Weizman, R, 2003) |
| "Significant weight gain is a side effect associated with olanzapine treatment in some patients." | 5.10 | Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients. ( Bogenschutz, M; Bustillo, JR; Hammond, R; Keith, S; Lauriello, J; Parker, K; Rowland, L, 2003) |
| "Weight gain is associated with treatment with olanzapine and other psychotropic agents." | 5.10 | Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial. ( Allison, DB; Breier, A; Cavazzoni, P; Roychowdhury, SM; Tanaka, Y, 2003) |
| "Olanzapine-induced weight gain is associated with a general increase in caloric intake." | 5.10 | Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. ( Apter, A; Constantini, N; Falk, B; Frishman, S; Gothelf, D; Kairi, M; Phillip, M; Poraz, I; Singer, P; Weizman, A; Zalsman, G; Zigel, L, 2002) |
| "It has been reported that nizatidine may reduce the weight gain in schizophrenic patients receiving olanzapine treatment." | 5.10 | Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain. ( Atmaca, M; Kuloglu, M; Tezcan, E; Ustundag, B, 2003) |
| "During up to 1 year of olanzapine therapy, either as monotherapy or in combination with lithium and/or fluoxetine, patients with bipolar disorder demonstrated significant improvement in mania and depression symptoms with a favorable safety profile." | 5.09 | Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. ( Gibson, PJ; Greaney, MG; Grundy, SL; Namjoshi, MA; Sanger, TM; Tohen, MF, 2001) |
| "Subjects (N=377) who met DSM-IV criteria for schizophrenia or schizoaffective disorder were randomly assigned to receive 2-6 mg/day of risperidone (mean modal dose=4." | 5.09 | A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. ( Conley, RR; Mahmoud, R, 2001) |
| "Adding the atypical neuroleptic risperidone to a serotonin reuptake inhibitor (SRI) has benefited patients with treatment-refractory obsessive-compulsive disorder (OCD)." | 5.09 | Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. ( Elliott, MA; Koran, LM; Ringold, AL, 2000) |
| " haloperidol) therapy, better clinical outcome, lower BBMI, and nonwhite race significantly affected weight gain." | 5.09 | Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. ( Basson, BR; Gilmore, JA; Kinon, BJ; Szymanski, KA; Taylor, CC; Tollefson, GD, 2001) |
| " A total of 115 patients with a DSM-IV diagnosis of bipolar disorder, manic or mixed, were randomized to olanzapine, 5 to 20 mg/d (n = 55), or placebo (n = 60)." | 5.09 | Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. ( Banov, MC; Breier, A; Francis, J; Grundy, SL; Jacobs, TG; Janicak, PG; McElroy, SL; Risser, R; Sanger, T; Tohen, M; Tollefson, GD; Toma, V; Zhang, F, 2000) |
| "We performed a retrospective analysis of 122 clinical records of 92 male patients with DSM-III-R schizophrenia to examine the relative weight gain liabilities of clozapine, risperidone, olanzapine, and sertindole compared with haloperidol." | 5.09 | Novel antipsychotics: comparison of weight gain liabilities. ( Berisford, MA; Goldstein, D; Kysar, L; Marder, SR; Mintz, J; Pashdag, J; Wirshing, DA; Wirshing, WC, 1999) |
| "The authors used a prospective, controlled, open study comparing body weight, body mass index, and related biological measures in mentally and physically healthy volunteers and olanzapine-treated patients with schizophrenia." | 5.09 | Association of olanzapine-induced weight gain with an increase in body fat. ( Ebenbichler, C; Eder, U; Fleischhacker, WW; Hofer, A; Hummer, M; Kemmler, G; Lechleitner, M; Mangweth, B; Weiss, E, 2001) |
| "The aim of this study was to estimate the long-term effectiveness of olanzapine as adjunctive therapy in patients with bipolar disorder who exhibited an inadequate response to mood stabilizers." | 5.09 | Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder. ( Benabarre, A; Colom, F; Corbella, B; Gastó, C; Gilaberte, I; Martínez-Arán, A; Reinares, M; Tohen, M; Vieta, E, 2001) |
| "Open-label olanzapine treatment was efficacious and well tolerated in the treatment of acute mania in youths with bipolar disorder." | 5.09 | A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. ( Biederman, J; Feldman, PD; Frazier, JA; Garfield, SB; Gonzalez-Heydrich, J; Jacobs, TG; Kim, GS; Nowlin, ZM; Rater, MA; Risser, RC; Sohma, M; Tarazi, RA; Tohen, M; Toma, V, 2001) |
| "This first clinical study of olanzapine in Japanese patients with schizophrenia was conducted to investigate the efficacy and safety of olanzapine." | 5.09 | Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: results of an open-label multicenter study in Japan. ( Ishigooka, J; Miura, S; Murasaki, M, 2001) |
| "This open-label clinical study was conducted for patients with schizophrenia in order to investigate the efficacy, safety and optimal dose of olanzapine." | 5.09 | Olanzapine optimal dose: results of an open-label multicenter study in schizophrenic patients. Olanzapine Late-Phase II Study Group. ( Ishigooka, J; Miura, S; Murasaki, M, 2000) |
| " Amantadine (100-300 mg/day) was started in 12 patients having a mean weight gain of 7." | 5.09 | Effect of amantadine on weight gain during olanzapine treatment. ( Deberdt, W; Floris, M; Lejeune, J, 2001) |
| "Weight change and the weight-related health factors of nonfasting serum glucose, serum cholesterol, and diastolic blood pressure levels were analyzed in patients with DSM-III-R schizophrenia and related disorders who received treatment with olanzapine for up to 3 years, and comparisons were made to patients treated with haloperidol." | 5.09 | Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. ( Basson, BR; Gilmore, JA; Kinon, BJ; Tollefson, GD, 2001) |
| " Weight gain has become an issue recently as a result of reports that 2 of the atypical antipsychotic agents, clozapine and olanzapine, are associated with a higher risk than other drugs of causing excessive weight gain." | 4.81 | Review of atypical antipsychotics and weight gain. ( Sussman, N, 2001) |
| " Risperidone is associated with relatively few motor side effects compared with the traditional antipsychotics, and weight gain is less likely with risperidone than with either clozapine or olanzapine." | 4.80 | Risperidone side effects. ( Conley, RR, 2000) |
| " The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only)." | 4.80 | Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations. ( , 1998) |
| " Clozapine seems to have the highest risk of weight gain, followed by olanzapine and quetiapine." | 4.80 | Atypical antipsychotics and weight gain--a systematic review. ( McAskill, R; Taylor, DM, 2000) |
| "Olanzapine, a serotonin-dopamine receptor antagonist, is one of the novel atypical antipsychotics that is effective against the positive and negative symptoms of schizophrenia with significantly fewer treatment-emergent extrapyramidal symptoms and less akathisia associated with traditional antipsychotics." | 4.80 | Adverse events related to olanzapine. ( Conley, RR; Meltzer, HY, 2000) |
| "Clinical safety data for treatment of acute schizophrenia with olanzapine, a new atypical antipsychotic agent, are summarized." | 4.79 | Safety of olanzapine. ( Beasley, CM; Tollefson, GD; Tran, PV, 1997) |
| "The authors explored the binge eating symptomatology in 74 patients receiving clozapine (N = 57) or olanzapine (N = 17), and compared body mass index (BMI, kg/m(2)) and weight gain in patients with and without binge eating symptomatology." | 3.72 | Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine. ( Hebebrand, J; König, IR; Linden, A; Martin, M; Remschmidt, H; Theisen, FM, 2003) |
| "Our results suggest that leptin may be associated with olanzapine- and clozapine-induced weight gain and that quetiapine appears to have modest influence and risperidone appears to have minimal influence on leptin and triglyceride levels and weight gain compared with olanzapine and clozapine." | 3.72 | Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. ( Atmaca, M; Kuloglu, M; Tezcan, E; Ustundag, B, 2003) |
| "Several clinical reports have demonstrated that most antipsychotics of the new generation, but not the typical antipsychotic haloperidol, induce weight gain in schizophrenic patients." | 3.72 | Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human. ( Kreilgaard, M; Mow, T; Pouzet, B; Velschow, S, 2003) |
| "Clinically relevant weight gain is clearly associated with olanzapine, and to lesser extent, with haloperidol and risperidone." | 3.72 | Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. ( Bobes, J; Fernández, I; Garcia-Garcia, M; García-Portilla, MP; Hernández, G; Rejas, J; Rico-Villademoros, F, 2003) |
| "The increasing use of olanzapine for treating adolescent patients has brought with it greater awareness of the recognized side effects of this medication, especially weight gain." | 3.72 | Hyperglycemia from olanzapine treatment in adolescents. ( Bloch, Y; Gothelf, D; Levkovitz, Y; Mendlovic, S; Ratzoni, G; Vardi, O, 2003) |
| "The role of olanzapine in treatment-resistant schizophrenia is still unresolved." | 3.71 | Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial. ( Chakos, M; Citrome, L; Czobor, P; Iskander, A; Lieberman, J; Lindenmayer, JP; Parker, B; Sheitman, B; Volavka, J, 2001) |
| "To evaluate weight gain associated with olanzapine, risperidone, and haloperidol treatment and its clinical risk factors in adolescent patients." | 3.71 | Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. ( Apter, A; Brand-Gothelf, A; Gal, G; Gothelf, D; Kikinzon, L; Phillip, M; Ratzoni, G; Reidman, J; Weizman, R, 2002) |
| "Conventional as well as newer antipsychotics cause weight gain, and, in the regulation of body weight, both insulin and leptin are hormones involved." | 3.71 | Insulin and leptin levels in patients with schizophrenia or related psychoses--a comparison between different antipsychotic agents. ( Hulting, AL; Melkersson, KI, 2001) |
| " In order to determine whether newer antipsychotic agents differ from each other with respect to weight gain, we compared two cohorts of patients with DSM-IV schizophrenia who had newly started treatment with either risperidone or olanzapine." | 3.71 | Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone. ( Ayrton, Z; Brar, JS; Ganguli, R, 2001) |
| "We describe here a case of olanzapine associated weight gain, hyperglycemia and neuroleptic malignant syndrome in a 64 year-old woman with a significant medical history." | 3.71 | Olanzapine associated weight gain, hyperglycemia and neuroleptic malignant syndrome: case report. ( Gibson, B; Kang, N; Malyuk, R; Procyshyn, RM, 2002) |
| "This study evaluated the effectiveness of a Weight Watchers program for patients with schizophrenia who had olanzapine-related weight gain and ascertained whether the severity of patients' psychiatric symptoms was correlated with the patients' success in losing weight." | 3.71 | A program for treating olanzapine-related weight gain. ( Ball, MP; Buchanan, RW; Coons, VB, 2001) |
| " However, accumulating evidence suggests that these agents, particularly clozapine and olanzapine, have serious side effects of their own, including weight gain and elevated glucose and triglyceride levels." | 3.71 | The effects of novel antipsychotics on glucose and lipid levels. ( Ballon, JS; Boyd, JA; Marder, SR; Meng, LR; Wirshing, DA; Wirshing, WC, 2002) |
| "The aim of this study was to evaluate the mechanisms underlying weight gain induced by the atypical antipsychotic, olanzapine." | 3.71 | Decrease of energy expenditure causes weight increase in olanzapine treatment - a case study. ( Franssila-Kallunki, A; Naukkarinen, H; Rissanen, A; Virkkunen, M; Wahlbeck, K, 2002) |
| "We report on three cases of acutely manic prepubertal children diagnosed with bipolar disorder who were treated with olanzapine in addition to their existing mood stabilizer regimens." | 3.70 | Mood stabilizer augmentation with olanzapine in acutely manic children. ( Chang, KD; Ketter, TA, 2000) |
| "Weight gain induced by clozapine or olanzapine appears to be associated with an increase in leptin level that cannot be attributed to dietary changes upon hospitalization." | 3.70 | Body weight and leptin plasma levels during treatment with antipsychotic drugs. ( Haack, M; Hinze-Selch, D; Kraus, T; Kühn, M; Pollmächer, T; Schuld, A; Uhr, M, 1999) |
| "H(2) antagonist treatment with olanzapine may be a valid medical strategy in preventing and/or reducing weight gain in patients with schizophrenia." | 3.70 | H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients. ( Bravi, D; Guarneri, L; Sacchetti, E, 2000) |
| "AP-induced weight gain is also associated with disruption of the hypothalamic-pituitary-gonadal axis." | 2.71 | The relationship of changes in leptin, neuropeptide Y and reproductive hormones to antipsychotic induced weight gain. ( de Castella, AR; Fitzgerald, PB; Kulkarni, J; Morris, MJ; Scaffidi, A, 2003) |
| " The treating clinician was free to vary or discontinue dosing and use additional medications." | 2.71 | A 1-year open-label trial of olanzapine in school-age children with schizophrenia. ( Adler, LE; Farley, GK; Novins, D; Ross, RG, 2003) |
| "Olanzapine is an effective and safe antipsychotic drug." | 2.41 | [Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring]. ( Baumann, P; Grasmäder, K; Hiemke, C; Rao, ML, 2001) |
| "Most traditional neuroleptics have a narrow therapeutic-to-toxic index, and thus, the novel antipsychotics are the result of a search to substantially widen the distance between the dose that treats psychosis and the one that produces adverse effects." | 2.40 | The relationship of pharmacology to side effects. ( Casey, DE, 1997) |
| " Considerable progress has been made in improving the motor side effect profile with the advent of clozapine and risperidone." | 2.39 | Side effect profiles of new antipsychotic agents. ( Casey, DE, 1996) |
| "Olanzapine and clozapine have been associated with the greatest weight gain of the newer antipsychotics." | 1.31 | Clinical issues associated with maintenance treatment of patients with schizophrenia. ( Guthrie, SK, 2002) |
| "Weight gain has been reported with nearly every antipsychotic drug on the market (molindone is an exception)." | 1.30 | Weight gain associated with antipsychotic drugs. ( Ganguli, R, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (17.65) | 18.2507 |
| 2000's | 69 (81.18) | 29.6817 |
| 2010's | 1 (1.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mao, M | 1 |
| Skogh, E | 1 |
| Scordo, MG | 1 |
| Dahl, ML | 1 |
| Powers, PS | 1 |
| Santana, CA | 1 |
| Bannon, YS | 1 |
| Guthrie, SK | 1 |
| Hermida, T | 1 |
| Franco, K | 1 |
| Hadi, F | 1 |
| Douyon, K | 1 |
| Wirshing, DA | 2 |
| Boyd, JA | 1 |
| Meng, LR | 1 |
| Ballon, JS | 1 |
| Marder, SR | 2 |
| Wirshing, WC | 2 |
| Levy, E | 1 |
| Margolese, HC | 1 |
| Chouinard, G | 1 |
| Goudie, AJ | 1 |
| Smith, JA | 1 |
| Halford, JC | 1 |
| Atmaca, M | 3 |
| Kuloglu, M | 3 |
| Tezcan, E | 3 |
| Gecici, O | 1 |
| Ustundag, B | 3 |
| Theisen, FM | 1 |
| Linden, A | 1 |
| König, IR | 1 |
| Martin, M | 1 |
| Remschmidt, H | 1 |
| Hebebrand, J | 1 |
| Lindenmayer, JP | 2 |
| Czobor, P | 2 |
| Volavka, J | 2 |
| Citrome, L | 2 |
| Sheitman, B | 2 |
| McEvoy, JP | 1 |
| Cooper, TB | 1 |
| Chakos, M | 2 |
| Lieberman, JA | 1 |
| Poyurovsky, M | 2 |
| Isaacs, I | 1 |
| Fuchs, C | 2 |
| Schneidman, M | 2 |
| Faragian, S | 1 |
| Weizman, R | 2 |
| Weizman, A | 3 |
| Bustillo, JR | 1 |
| Lauriello, J | 1 |
| Parker, K | 1 |
| Hammond, R | 1 |
| Rowland, L | 1 |
| Bogenschutz, M | 1 |
| Keith, S | 1 |
| Cavazzoni, P | 2 |
| Tanaka, Y | 1 |
| Roychowdhury, SM | 1 |
| Breier, A | 3 |
| Allison, DB | 2 |
| Gupta, S | 3 |
| Pouzet, B | 1 |
| Mow, T | 1 |
| Kreilgaard, M | 1 |
| Velschow, S | 1 |
| Bobes, J | 1 |
| Rejas, J | 1 |
| Garcia-Garcia, M | 1 |
| Rico-Villademoros, F | 1 |
| García-Portilla, MP | 1 |
| Fernández, I | 1 |
| Hernández, G | 1 |
| D'Amico, G | 1 |
| Cedro, C | 1 |
| Muscatello, MR | 1 |
| Pandolfo, G | 1 |
| Di Rosa, AE | 1 |
| Zoccali, R | 1 |
| La Torre, D | 1 |
| D'Arrigo, C | 1 |
| Spina, E | 1 |
| Bloch, Y | 1 |
| Vardi, O | 1 |
| Mendlovic, S | 1 |
| Levkovitz, Y | 1 |
| Gothelf, D | 3 |
| Ratzoni, G | 2 |
| McIntyre, RS | 1 |
| Mancini, DA | 1 |
| Basile, VS | 1 |
| Srinivasan, J | 1 |
| Kennedy, SH | 1 |
| Pae, CU | 1 |
| Kim, JJ | 1 |
| Lee, KU | 1 |
| Lee, CU | 1 |
| Bahk, WM | 1 |
| Lee, SJ | 1 |
| Lee, C | 1 |
| Paik, IH | 1 |
| Fitzgerald, PB | 1 |
| Scaffidi, A | 1 |
| Morris, MJ | 1 |
| de Castella, AR | 1 |
| Kulkarni, J | 1 |
| Littrell, KH | 1 |
| Hilligoss, NM | 1 |
| Kirshner, CD | 1 |
| Petty, RG | 1 |
| Johnson, CG | 1 |
| Kelly, DL | 1 |
| Kreyenbuhl, J | 1 |
| Love, RC | 1 |
| Van-Duong, Q | 1 |
| Conley, RR | 4 |
| Ross, RG | 1 |
| Novins, D | 1 |
| Farley, GK | 1 |
| Adler, LE | 1 |
| Deng, C | 1 |
| Weston-Green, KL | 1 |
| Han, M | 1 |
| Huang, XF | 1 |
| Casey, DE | 4 |
| Beasley, CM | 2 |
| Tollefson, GD | 4 |
| Tran, PV | 1 |
| Droney, T | 2 |
| Al-Samarrai, S | 2 |
| Keller, P | 2 |
| Frank, B | 2 |
| Kraus, T | 1 |
| Haack, M | 1 |
| Schuld, A | 1 |
| Hinze-Selch, D | 1 |
| Kühn, M | 1 |
| Uhr, M | 1 |
| Pollmächer, T | 1 |
| Aquila, R | 1 |
| Emanuel, M | 1 |
| Kysar, L | 1 |
| Berisford, MA | 1 |
| Goldstein, D | 1 |
| Pashdag, J | 1 |
| Mintz, J | 1 |
| Sheitman, BB | 1 |
| Bird, PM | 1 |
| Binz, W | 1 |
| Akinli, L | 1 |
| Sanchez, C | 1 |
| Ganguli, R | 2 |
| Masand, PS | 1 |
| Bryden, KE | 1 |
| Kopala, LC | 2 |
| Osser, DN | 1 |
| Najarian, DM | 1 |
| Dufresne, RL | 1 |
| Chang, KD | 1 |
| Ketter, TA | 1 |
| Ohaeri, JU | 1 |
| Meltzer, HY | 1 |
| Taylor, DM | 1 |
| McAskill, R | 1 |
| Karagianis, J | 1 |
| Sacchetti, E | 1 |
| Guarneri, L | 1 |
| Bravi, D | 1 |
| Koran, LM | 1 |
| Ringold, AL | 1 |
| Elliott, MA | 1 |
| Tohen, M | 3 |
| Jacobs, TG | 2 |
| Grundy, SL | 2 |
| McElroy, SL | 1 |
| Banov, MC | 1 |
| Janicak, PG | 1 |
| Sanger, T | 1 |
| Risser, R | 1 |
| Zhang, F | 1 |
| Toma, V | 2 |
| Francis, J | 1 |
| Ishigooka, J | 2 |
| Murasaki, M | 2 |
| Miura, S | 2 |
| Nguyen, M | 1 |
| Murphy, T | 1 |
| Wetterling, T | 1 |
| Jones, B | 1 |
| Basson, BR | 3 |
| Walker, DJ | 1 |
| Crawford, AM | 1 |
| Kinon, BJ | 3 |
| Gilmore, JA | 2 |
| Potenza, MN | 1 |
| McDougle, CJ | 1 |
| Floris, M | 1 |
| Lejeune, J | 1 |
| Deberdt, W | 1 |
| Melkersson, KI | 1 |
| Hulting, AL | 1 |
| Mahmoud, R | 1 |
| Zorn, SH | 1 |
| Brar, JS | 1 |
| Ayrton, Z | 1 |
| Taylor, CC | 1 |
| Szymanski, KA | 1 |
| Sanger, TM | 1 |
| Gibson, PJ | 1 |
| Namjoshi, MA | 1 |
| Greaney, MG | 1 |
| Tohen, MF | 1 |
| Umbricht, D | 1 |
| Flury, H | 1 |
| Bridler, R | 1 |
| Ball, MP | 1 |
| Coons, VB | 1 |
| Buchanan, RW | 1 |
| Lieberman, J | 1 |
| Parker, B | 1 |
| Iskander, A | 1 |
| Eder, U | 1 |
| Mangweth, B | 1 |
| Ebenbichler, C | 1 |
| Weiss, E | 1 |
| Hofer, A | 1 |
| Hummer, M | 1 |
| Kemmler, G | 1 |
| Lechleitner, M | 1 |
| Fleischhacker, WW | 1 |
| Dewan, VK | 1 |
| Vieta, E | 1 |
| Reinares, M | 1 |
| Corbella, B | 1 |
| Benabarre, A | 1 |
| Gilaberte, I | 1 |
| Colom, F | 1 |
| Martínez-Arán, A | 1 |
| Gastó, C | 1 |
| Haapasalo-Pesu, KM | 1 |
| Saarijärvi, S | 1 |
| Sussman, N | 1 |
| Frazier, JA | 1 |
| Biederman, J | 1 |
| Feldman, PD | 1 |
| Rater, MA | 1 |
| Tarazi, RA | 1 |
| Kim, GS | 1 |
| Garfield, SB | 1 |
| Sohma, M | 1 |
| Gonzalez-Heydrich, J | 1 |
| Risser, RC | 1 |
| Nowlin, ZM | 1 |
| Simpson, MM | 1 |
| Goetz, RR | 1 |
| Devlin, MJ | 1 |
| Goetz, SA | 1 |
| Walsh, BT | 1 |
| Rao, ML | 1 |
| Hiemke, C | 1 |
| Grasmäder, K | 1 |
| Baumann, P | 1 |
| Brand-Gothelf, A | 1 |
| Reidman, J | 1 |
| Kikinzon, L | 1 |
| Gal, G | 1 |
| Phillip, M | 2 |
| Apter, A | 2 |
| Riccitelli, G | 1 |
| Baker, N | 1 |
| Malyuk, R | 1 |
| Gibson, B | 1 |
| Procyshyn, RM | 1 |
| Kang, N | 1 |
| Falk, B | 1 |
| Singer, P | 1 |
| Kairi, M | 1 |
| Zigel, L | 1 |
| Poraz, I | 1 |
| Frishman, S | 1 |
| Constantini, N | 1 |
| Zalsman, G | 1 |
| Pashinian, A | 1 |
| Gil-Ad, I | 1 |
| Maayan, R | 1 |
| Sowell, MO | 1 |
| Mukhopadhyay, N | 1 |
| Shankar, S | 1 |
| Steinberg, HO | 1 |
| Dananberg, J | 1 |
| Webster, D | 1 |
| Devarajan, S | 1 |
| Gallant, J | 1 |
| Harris, A | 1 |
| Virkkunen, M | 1 |
| Wahlbeck, K | 1 |
| Rissanen, A | 1 |
| Naukkarinen, H | 1 |
| Franssila-Kallunki, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Transcranial Magnetic Stimulation for Individuals With Tourette's Syndrome[NCT00529308] | Phase 2 | 20 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Aripiprazole for Clozapine Associated Medical Morbidity[NCT00345033] | Phase 4 | 38 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| Outcome Evaluation of Solutions for Wellness and Team Solutions Program in Patients With Severe Mental Illness[NCT00661869] | 295 participants (Actual) | Interventional | 2006-09-30 | Completed | |||
| A Placebo-Controlled, Cross-Over Trial of Aripiprazole Added to Obese Olanzapine-Treated Patients With Schizophrenia[NCT00351936] | Phase 4 | 16 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| A Clinical Trial Of Weight Reduction in Schizophrenia[NCT00158366] | 261 participants (Actual) | Interventional | 2004-05-31 | Completed | |||
| An Open Label Trial of Ziprasidone as an Adjuvant for Clozapine- or Olanzapine-Associated Diabetes Mellitus or Impaired Fasting Glucose in Chronic Schizophrenia[NCT00351000] | Phase 4 | 24 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Reduction of Body Weight in Olanzapine Treated Schizophrenia Patients by Adjunctive Supplementation of Antioxidants (Vitamins E + C) Plus Omega-3 Fatty Acids[NCT00211562] | Phase 3 | 20 participants (Actual) | Interventional | 2005-10-31 | Terminated | ||
| The Investigation of the Impact of Atypical Antipsychotics on Brain Functioning in Youths With Conduct Disorder[NCT01867398] | 12 participants (Actual) | Observational | 2013-04-29 | Terminated | |||
| Effects of Atypical Antipsychotics on Appetite and Eating Behavior of Schizophrenia Patients: Analysis for Three Drugs, Olanzapine, Risperidone, and Aripiprazole, Known to Induce Different Degrees of Weight Gain[NCT01043250] | 81 participants (Actual) | Observational | 2009-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks
| Intervention | participants (Number) |
|---|---|
| Active | 2 |
| Sham | 8 |
"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks
| Intervention | participants (Number) |
|---|---|
| Active | 1 |
| Sham | 0 |
Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks
| Intervention | µV (Mean) |
|---|---|
| Active | 56.5 |
| Sham | 63.8 |
Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks
| Intervention | µV (Mean) |
|---|---|
| Active | 56 |
| Sham | 59.8 |
Y-GTSS is a clinician-rated scale used to assess tic severity. Motor and phonic tics are rated separately from 0 to 5 on several scales including number, frequency, intensity, complexity, and interference. Thus Motor and Phonic Tic scores can range from 0 to 25; the combined Total Tic Score ranges from 0 to 50. There is also an Impairment score that rates the overall burden due to tics. The Impairment scale yields a single score from 0 to 50 with higher scores indicating higher levels of overall impairment associated with tics. (NCT00529308)
Timeframe: 3 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Active | 29.5 |
| Sham | 31.5 |
A comparison between aripiprazole group and placebo group of change in Body Mass Index (BMI) measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | kg/m^2 (Mean) |
|---|---|
| Aripiprazole | -0.52 |
| Placebo | 0.03 |
A comparison between the aripiprazole group and placebo group in change in glucose metabolism measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | min^-1 (Mean) |
|---|---|
| Aripiprazole | 0.003 |
| Placebo | -0.005 |
A comparison between aripiprazole group and placebo group of change in insulin resistance measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | HOMA score (Mean) |
|---|---|
| Aripiprazole | 0.6 |
| Placebo | 0.65 |
A comparison of aripiprazole group and placebo group in change in total cholesterol measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -15.3 |
| Placebo | 5.6 |
(NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -5.9 |
| Placebo | -7.3 |
A comparison between aripiprazole group and placebo group in change in weight measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | kg (Mean) |
|---|---|
| Aripiprazole | -1.5 |
| Placebo | 0.3 |
Evaluating change in Body Mass Index (BMI) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | kg/m^2 (Mean) |
|---|---|
| Aripiprazole | -0.4 |
| Placebo | 0.3 |
Evaluating change in fasting total cholesterol between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -3 |
| Placebo | 9 |
Evaluating change in high-density lipoprotein cholesterol (HDL-C) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | 0.4 |
| Placebo | 0.6 |
Evaluating change in low-density lipoprotein (LDL) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -0.2 |
| Placebo | 3.1 |
Evaluating change in triglyceride levels between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -51.7 |
| Placebo | 47.6 |
Evaluating change in waist-hip ratio (WHR) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | cm (Mean) |
|---|---|
| Aripiprazole | 0.0 |
| Placebo | 0.0 |
Evaluating change in weight (lbs) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | lbs (Mean) |
|---|---|
| Aripiprazole | -2.9 |
| Placebo | 2.1 |
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting glucose levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | mg/dL (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 5 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -4.5 |
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting insulin levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | microIU/L (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 1 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -0.9 |
14 reviews available for pirenzepine and Weight Gain
| Article | Year |
|---|---|
Safety in treating bipolar disorder.
Topics: Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clozapine; Diabetes Melli | 2003 |
Side effect profiles of new antipsychotic agents.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Dyskinesia, Drug-Induced; | 1996 |
Safety of olanzapine.
Topics: Acute Disease; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Blood Pressure; Clini | 1997 |
The relationship of pharmacology to side effects.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; D | 1997 |
Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Agranulocytosis; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Central Nervous Syst | 1998 |
Risperidone side effects.
Topics: Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Humans; Hyperprolactinemia; Inc | 2000 |
Adverse events related to olanzapine.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Body Mass In | 2000 |
Atypical antipsychotics and weight gain--a systematic review.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Dibenzothiepins; | 2000 |
Bodyweight gain with atypical antipsychotics. A comparative review.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Mental Disorders; Olan | 2001 |
Weight change and atypical antipsychotic treatment in patients with schizophrenia.
Topics: Antipsychotic Agents; Behavior Therapy; Benzodiazepines; Dose-Response Relationship, Drug; Follow-Up | 2001 |
Antipsychotic-induced weight gain: a review of the literature.
Topics: Adult; Antipsychotic Agents; Behavior Therapy; Benzodiazepines; Body Mass Index; Female; Humans; Mal | 2001 |
The pharmacology of weight gain with antipsychotics.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Eating; Humans; Olanz | 2001 |
Review of atypical antipsychotics and weight gain.
Topics: Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Clinical Trials as Topic; C | 2001 |
[Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring].
Topics: Antipsychotic Agents; Benzodiazepines; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Dose-Respon | 2001 |
30 trials available for pirenzepine and Weight Gain
| Article | Year |
|---|---|
Olanzapine in the treatment of anorexia nervosa: an open label trial.
Topics: Adolescent; Adult; Anorexia Nervosa; Benzodiazepines; Female; Humans; Male; Middle Aged; Olanzapine; | 2002 |
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Cholesterol; Clozapine; Double-Bl | 2003 |
Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study.
Topics: Adrenergic Uptake Inhibitors; Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Double- | 2003 |
Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients.
Topics: Adolescent; Adult; Analysis of Variance; Benzodiazepines; Double-Blind Method; Female; Fluoxetine; H | 2003 |
Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Benzodiazepines; Double-Blind Method; Drug Therapy, C | 2003 |
Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Resistance; Female; Humans; Male; Middle Aged; Ob | 2003 |
Antipsychotic-induced weight gain: bipolar disorder and leptin.
Topics: Adolescent; Adult; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Body M | 2003 |
Effect of nizatidine on olanzapine-associated weight gain in schizophrenic patients in Korea: a pilot study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Histamine H2 Antagonists; Humans; Male; Nizati | 2003 |
Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Histamine H2 Antagonists; | 2003 |
The relationship of changes in leptin, neuropeptide Y and reproductive hormones to antipsychotic induced weight gain.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Gonadal Steroid Hormones; Humans; Leptin; Midd | 2003 |
The effects of an educational intervention on antipsychotic-induced weight gain.
Topics: Adult; Antipsychotic Agents; Attitude to Health; Benzodiazepines; Body Mass Index; Female; Health Kn | 2003 |
A 1-year open-label trial of olanzapine in school-age children with schizophrenia.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Child; Drug Resistance; Female; Humans; Male; Ola | 2003 |
Olanzapine for schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Constipation; Costs and Cost Analysis; Dizziness; Dose-Respon | 1997 |
Novel antipsychotics: comparison of weight gain liabilities.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Haloperidol; Humans; I | 1999 |
Olanzapine increases weight and serum triglyceride levels.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Female; Hospitalizat | 1999 |
Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
Topics: Adult; Benzodiazepines; Drug Administration Schedule; Drug Therapy, Combination; Fluoxetine; Humans; | 2000 |
Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dou | 2000 |
Olanzapine optimal dose: results of an open-label multicenter study in schizophrenic patients. Olanzapine Late-Phase II Study Group.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Brief Psychiatric | 2000 |
Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Blood Pressure; Body Mass Index; Body W | 2001 |
Effect of amantadine on weight gain during olanzapine treatment.
Topics: Adult; Amantadine; Antipsychotic Agents; Benzodiazepines; Dopamine Agents; Female; Humans; Male; Ola | 2001 |
A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Double-Blind Method; Drug Admi | 2001 |
Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.
Topics: Adult; Age Factors; Antipsychotic Agents; Appetite; Benzodiazepines; Body Mass Index; Body Weight; B | 2001 |
Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Depressive Disorder; Double-Blind Me | 2001 |
Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: results of an open-label multicenter study in Japan.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Anxiety; Benzodiazepines; Female; Humans; Japa | 2001 |
Association of olanzapine-induced weight gain with an increase in body fat.
Topics: Adipose Tissue; Adult; Antipsychotic Agents; Benzodiazepines; Body Composition; Body Mass Index; Fee | 2001 |
Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Disorders of Excessive Somnolence; D | 2001 |
A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder.
Topics: Abdominal Pain; Adolescent; Antipsychotic Agents; Appetite; Benzodiazepines; Bipolar Disorder; Brief | 2001 |
Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Eating; Energy Inta | 2002 |
Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Double-Blind Method; Drug Therapy, Co | 2002 |
Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Female; Glucose Clamp Technique; Huma | 2002 |
41 other studies available for pirenzepine and Weight Gain
| Article | Year |
|---|---|
Interindividual variation in olanzapine concentration influenced by UGT1A4 L48V polymorphism in serum and upstream FMO polymorphisms in cerebrospinal fluid.
Topics: Antipsychotic Agents; Benzodiazepines; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Female; Hum | 2012 |
Clinical issues associated with maintenance treatment of patients with schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Clozapine; Continuity of Patient Ca | 2002 |
Weight gain associated with atypical antipsychotics.
Topics: Adolescent; Benzodiazepines; Child; Dopamine Antagonists; Female; Haloperidol; Humans; Male; Obesity | 2002 |
The effects of novel antipsychotics on glucose and lipid levels.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL | 2002 |
The effects of novel antipsychotics on glucose and lipid levels.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL | 2002 |
The effects of novel antipsychotics on glucose and lipid levels.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL | 2002 |
The effects of novel antipsychotics on glucose and lipid levels.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL | 2002 |
Topiramate produced weight loss following olanzapine-induced weight gain in schizophrenia.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Drug Therapy, Combin | 2002 |
Characterization of olanzapine-induced weight gain in rats.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Female; Olanzapine; Pirenzepine; Rats; Rats, Wistar; | 2002 |
Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Diagnostic and Statistical Manual of Menta | 2003 |
Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Bulimia; Clozapine; Femal | 2003 |
Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Clozapine; Dibenzothiazepines; Female | 2003 |
Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Body Weight; Diet; Disease Models, Animal; Dose-Resp | 2003 |
Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Ambulatory Care; Antipsychotic Agents; Benzodiazepin | 2003 |
Hyperglycemia from olanzapine treatment in adolescents.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Diabetes Mellitus, Type 2; Female; | 2003 |
Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Clozapine; Dibenzothiazepines; Drug The | 2003 |
Olanzapine treatment decreases the density of muscarinic M2 receptors in the dorsal vagal complex of rats.
Topics: Animals; Antipsychotic Agents; Autoradiography; Benzodiazepines; Binding, Competitive; Female; Gene | 2007 |
Olanzapine-induced weight gain.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Middle Aged; Olanzapine; P | 1998 |
Body weight and leptin plasma levels during treatment with antipsychotic drugs.
Topics: Adipose Tissue; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body W | 1999 |
Olanzapine: weight gain and therapeutic efficacy.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Middle Aged; Olanzapine; P | 1999 |
Weight gain and antipsychotic medications.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Obesity; Olanzapine; Pirenzepine; Risperid | 1999 |
Olanzapine-induced elevation of plasma triglyceride levels.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Drug Administr | 1999 |
Weight gain associated with antipsychotic drugs.
Topics: Administration, Oral; Antipsychotic Agents; Benzodiazepines; Clozapine; Delayed-Action Preparations; | 1999 |
Relative weight gain among antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Obesity; Olanzapine; Pirenzepine; Risperid | 1999 |
Body mass index increase of 58% associated with olanzapine.
Topics: Adolescent; Benzodiazepines; Body Mass Index; Humans; Male; Obesity; Olanzapine; Pirenzepine; Schizo | 1999 |
Mood stabilizer augmentation with olanzapine in acutely manic children.
Topics: Antimanic Agents; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Benzodiazepin | 2000 |
Naturalistic study of olanzapine in treatment-resistant schizophrenia and acute mania, depression and obsessional disorder.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Depressive Disorde | 2000 |
Olanzapine and weight gain.
Topics: Adult; Benzodiazepines; Female; Humans; Obesity; Olanzapine; Pirenzepine; Psychotic Disorders; Selec | 2000 |
H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients.
Topics: Adult; Benzodiazepines; Brief Psychiatric Rating Scale; Histamine H2 Antagonists; Humans; Male; Niza | 2000 |
Olanzapine and hypertriglyceridemia.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Child; Humans; Hypertriglyceridemia; Male; | 2001 |
Reply to comments on "Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study".
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Child; Child Development Disorders, Pervas | 2001 |
Insulin and leptin levels in patients with schizophrenia or related psychoses--a comparison between different antipsychotic agents.
Topics: Adult; Aged; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass I | 2001 |
Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Female; Follow-Up Studies; Humans; Ma | 2001 |
Cognitive behavior therapy for weight gain.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clozapine; Cognitive Behavioral Ther | 2001 |
A program for treating olanzapine-related weight gain.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Diet, Redu | 2001 |
Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Drug Resistance; Female; Human | 2001 |
Re: Weight change with antipsychotic use.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Weight; Female; Fructose; Humans; Male; Olanzapin | 2001 |
Olanzapine induces remarkable weight gain in adolescent patients.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Olanzapine; Pirenzepine; Ps | 2001 |
Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Clozapine; Drug Administration Schedu | 2001 |
Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Male; Mental Disorde | 2002 |
Weight gain and hyperglycaemia associated with olanzapine.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Female; Humans; Hyperglycemia; Olanzapine; Pirenz | 2002 |
Olanzapine associated weight gain, hyperglycemia and neuroleptic malignant syndrome: case report.
Topics: Antipsychotic Agents; Benzodiazepines; Female; Humans; Hyperglycemia; Middle Aged; Neuroleptic Malig | 2002 |
Extreme weight gain in a youth with schizophrenia: risk/benefit considerations.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Clozapine; Follow-Up Stud | 2002 |
Decrease of energy expenditure causes weight increase in olanzapine treatment - a case study.
Topics: Antipsychotic Agents; Benzodiazepines; Calorimetry, Indirect; Energy Metabolism; Humans; Male; Middl | 2002 |